Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS).
II. Determine the side-effects and benefits associated with DAP.
|Study Design:||Allocation: Randomized
Primary Purpose: Treatment
|Study Start Date:||August 1994|
|Estimated Study Completion Date:||June 1998|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004832
|Study Chair:||Donald B. Sanders||Duke University|